OBJECTIVE: It has been reported that aspirin and other non-steroidal anti-inflammatory drugs (NSAID) may protect against dementia of Alzheimer's type and/or vascular dementia. However, co-morbidity and the dose of aspirin may be critical. A major indication for low-dose aspirin is prophylaxis after stroke and transient ischaemic attacks, conditions that may obscure an anti-dementia effect by the drug. Alternatively, low-dose aspirin may be insufficient if the protective effect is due to an anti-inflammatory mechanism. The aim of this study was to assess whether high-dose or low-dose aspirin may protect against Alzheimer's dementia in subjects aged > or =80 years. For comparison, effects of (other) NSAID, paracetamol and D-propoxyphene were studied. METHODS: Global, cross-sectional, and longitudinal (1991-2000) epidemiological analyses of clinical, cognitive and drug treatment data on 702 individuals 80 years old or more (351 twin pairs of same sex), all alive at inclusion: mean age 83.9 years (80-99 years). Calculations were made with logistic regression of associations between use of various analgesics and cognitive function, after adjustment for age, gender, and cardiovascular and cerebrovascular diseases. RESULTS: Users of high-dose aspirin had significantly lower prevalence of Alzheimer's dementia and better-maintained cognitive function than non-users. There were numerically similar but not significant associations with use of low-dose aspirin and other NSAID. There were no such associations with use of either paracetamol or D-propoxyphene. CONCLUSION: Aspirin might protect against Alzheimer's disease, but controlled trials are warranted.
OBJECTIVE: It has been reported that aspirin and other non-steroidal anti-inflammatory drugs (NSAID) may protect against dementia of Alzheimer's type and/or vascular dementia. However, co-morbidity and the dose of aspirin may be critical. A major indication for low-dose aspirin is prophylaxis after stroke and transient ischaemic attacks, conditions that may obscure an anti-dementia effect by the drug. Alternatively, low-dose aspirin may be insufficient if the protective effect is due to an anti-inflammatory mechanism. The aim of this study was to assess whether high-dose or low-dose aspirin may protect against Alzheimer's dementia in subjects aged > or =80 years. For comparison, effects of (other) NSAID, paracetamol and D-propoxyphene were studied. METHODS: Global, cross-sectional, and longitudinal (1991-2000) epidemiological analyses of clinical, cognitive and drug treatment data on 702 individuals 80 years old or more (351 twin pairs of same sex), all alive at inclusion: mean age 83.9 years (80-99 years). Calculations were made with logistic regression of associations between use of various analgesics and cognitive function, after adjustment for age, gender, and cardiovascular and cerebrovascular diseases. RESULTS: Users of high-dose aspirin had significantly lower prevalence of Alzheimer's dementia and better-maintained cognitive function than non-users. There were numerically similar but not significant associations with use of low-dose aspirin and other NSAID. There were no such associations with use of either paracetamol or D-propoxyphene. CONCLUSION:Aspirin might protect against Alzheimer's disease, but controlled trials are warranted.
Authors: B A in t' Veld; A Ruitenberg; A Hofman; L J Launer; C M van Duijn; T Stijnen; M M Breteler; B H Stricker Journal: N Engl J Med Date: 2001-11-22 Impact factor: 91.245
Authors: Peter P Zandi; James C Anthony; Kathleen M Hayden; Kala Mehta; Lawrence Mayer; John C S Breitner Journal: Neurology Date: 2002-09-24 Impact factor: 9.910
Authors: G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman Journal: Neurology Date: 1993-02 Impact factor: 9.910
Authors: Nicola Veronese; Ai Koyanagi; Brendon Stubbs; Marco Solmi; Michele Fornaro; Brisa S Fernandes; Christoph Mueller; Trevor Thompson; André F Carvalho; Stefania Maggi Journal: Int J Geriatr Psychiatry Date: 2017-08-06 Impact factor: 3.485
Authors: C A Szekely; R C Green; J C S Breitner; T Østbye; A S Beiser; M M Corrada; H H Dodge; M Ganguli; C H Kawas; L H Kuller; B M Psaty; S M Resnick; P A Wolf; A B Zonderman; K A Welsh-Bohmer; P P Zandi Journal: Neurology Date: 2008-05-28 Impact factor: 9.910